Navigating climate-focused AI funding offers a unique milestone for turning research concepts into transformative tools. CEO Aaron Schacht describes how BiomEdit’s Bezos-funded “digital twin” work aims to model genetics, feed and microbiome to predict performance and methane reduction, creating a platform that could serve both producers and future commercial partners.

Harnessing the power of real-world evidence is critical to scaling precision medicine. Christina Lopes, Co-Founder & CEO of FidoCure, shares how the company built a canine cancer dataset and leveraged AI to transform data points into targeted therapies, driving adoption beyond oncology specialists and enabling validated and scalable solutions.

A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.